Results 31 to 40 of about 36,254 (205)

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Analytical Cellular Pathology, 2020
Background. Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. Objective.
Yan Huang, Linli Duan, Wenjun He, Cheng Hong, Yehui Guo, Xinni Wang, Nuofu Zhang, Yanghang Chen, Tao Wang, Jian Wang, Chunli Liu   +10 more
doaj   +1 more source

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Frontiers in Pharmacology, 2022
Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or ...
Tingting Zhao, Xuening Li, Yanwei Chen, Jie Du, Xiaodong Chen, Dalong Wang, Liyan Wang, Shan Zhao, Changyuan Wang, Changyuan Wang, Qiang Meng, Qiang Meng, Huijun Sun, Huijun Sun, Kexin Liu, Kexin Liu, Jingjing Wu, Jingjing Wu   +17 more
doaj   +1 more source

Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage [PDF]

, 2018
Information about Rivaroxaban plasma levels (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking ...
Thilemann, Sebastian, Kägi, Georg, Sandor, Peter S, Engelter, Stefan T, Cappellari, Manuel, Emmanuel De Maistre, De Marchis, Gian Marco, Manuel Cappellari, Susanne Wegener, Berge, Eivind, Sebastian Thilemann, De Maistre, Emmanuel, Nils Peters, Béjot, Yannick, Schädelin, Sabine, Stefan T. Engelter, Eivind Berge, Gian Marco De Marchis, Zini, Andrea, Monika Kapauer, Zedde, Marialuisa, David Werring, Alexandros A. Polymeris, null null, Guillaume Turc, Andrea Zini, Andreas Luft, Marcel Arnold, Kapauer, Monika, Patrik Michel, Seiffge, David J, Traenka, Christopher, Arnold, Marcel, Turc, Guillaume, Marialuisa Zedde, Fischer, Urs, Dimtrios A. Tsakiris, Sabine Schädelin, Cordonnier, Charlotte, Werring, David, Urs Fischer, Jochen Vehoff, Luft, Andreas, David J. Seiffge, Michel, Patrik, Ilaria Maestrini, Charlotte Cordonnier, Sirimarco, Gaia, Tsakiris, Dimitrios A, Bonati, Leo H, Leo H. Bonati, Vehoff, Jochen, Maestrini, Ilaria, Georg Kägi, Peters, Nils, Yannick Béjot, Gaia Sirimarco, Philippe A. Lyrer, Tsakiris, Dimtrios A, Lyrer, Philippe A, Polymeris, Alexandros A, Gilles Rodier, Rodier, Gilles, Christopher Traenka, Wegener, Susanne, Peter S. Sandor   +65 more
core   +1 more source

Rivaroxaban versus warfarin for the management of left ventricle thrombus

The Egyptian Heart Journal, 2021
Background Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with ...
Monirah A. Albabtain, Yahya Alhebaishi, Ola Al-Yafi, Hatim Kheirallah, Adel Othman, Haneen Alghosoon, Amr A. Arafat, Ahmed Alfagih   +7 more
doaj   +1 more source

Thromboprophylaxis for Children Post‐Fontan Procedure: Insights From the UNIVERSE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Patients with single‐ventricle physiology who undergo the Fontan procedure are at risk for thrombotic events associated with significant morbidity and mortality.
Brian W. McCrindle, Alan D. Michelson, Andrew H. Van Bergen, Estela Suzana Horowitz, Juan Pablo Sandoval, Henri Justino, Kevin C. Harris, John L. Jefferies, Liza Miriam Pina, Colleen Peluso, Kimberly Nessel, Wentao Lu, Jennifer S. Li   +12 more
doaj   +1 more source

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice [PDF]

, 2018
Kavitha Vimalesvaran,1 Seth J Dockrill,1 Diana A Gorog1–3 1Department of Cardiology, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, UK; 2School of Life and Medical Sciences, Postgraduate Medical School, University of ...
Gorog DA, Diana A Gorog, Seth Dockrill, Kavitha Vimalesvaran, Vimalesvaran K, Gorog, Diana, Vimalesvaran, Kavitha, Dockrill SJ, Dockrill, Seth J   +8 more
core   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice

Scientific Reports, 2017
Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang, Junjie Shao, Ruifeng Hu, Haimei Chen, Ping Xie, Chang Liu   +5 more
doaj   +1 more source

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement [PDF]

, 2020
BACKGROUND Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.
Makkar, Raj R, Giustino, Gennaro, Zazula, Ana, Søndergaard, Lars, Wildgoose, Peter, Tchétché, Didier, Möllmann, Helge, Welsh, Robert C., Kini, Annapoorna, Curzen, Nicholas, Mack, Michael, Welsh, Robert C, Thomitzek, Karen, Volkl, Albert A, De Backer, Ole, GALILEO, Moellmann, Helge, Dangas, George D., Schäfer, Ulrich, Guimaraes, Ana H. C., van Amsterdam, Ronald G M, Tijssen, Jan G.P., Sondergaard, Lars, van Amsterdam, Ronald G. M., Schaefer, Ulrich, Moreno, Raúl, Gullestad, Lars, Guimarães, Ana H C, Vranckx, Pascal, Guimarães, Ana H.C., GALILEO Investigators, Dangas, George D, Kreuzpointner, Robert, van Amsterdam, Ronald G.M., Tijssen, Jan G P, Woehrle, Jochen, Windecker, Stephan, Volkl, Albert A., Herrmann, Howard C., Baldus, Stephan, von Lewinski, Dirk, Seeger, Julia, Makkar, Raj R., Gilard, Martine, Tijssen, Jan G. P., Wöhrle, Jochen, Herrmann, Howard C, Valgimigli, Marco, Mehran, Roxana   +48 more
core   +2 more sources

Rivaroxaban Attenuates the Cardiovascular PAR1-Related Inflammation, Fibrosis and Atherogenicity in Experimental Hypertensive/ Hypercholesterolemia Rat Model [PDF]

The Egyptian Journal of Histology
Introduction: Hypertension and hypercholesterolemia serve as a predisposing component for cardiovascular disorders. As an oral anticoagulant, Rivaroxaban is used to preclude and eliminate venous thrombosis, atrial fibrillation and coronary artery ...
Hanan Shamardl, Eman Hussien, Marwa Sofi, Sawsan Sadik   +3 more
doaj   +1 more source